Ascendis Pharma A/S
SKYTROFA
growth disorders
Resolved
187days ago
Catalyst readout · Jan 1, 2026
What's at stake
A key catalyst for SKYTROFA (growth disorders) is expected Jan 1, 2026.
Primary source
· SEC 6-K
verified 15h ago
“Ongoing Phase 3 HighLiGHts basket trial across a range of established growth disorders including idiopathic short stature (ISS), SHOX deficiency, Turner syndrome, and small for gestational age (SGA).”